Interest in and Preference for Long-acting Injectable Antiretroviral Therapy in the Era of Approved Cabotegravir/Rilpivirine Among Reproductive-aged Women in the US South.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 38943370.
- Also identified by DOI 10.1093/cid/ciae331 and PMC identifier 11797392.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Among 103 reproductive-aged women with human immunodeficiency virus (HIV) in the US South surveyed post-approval of long-acting injectable (LAI) cabotegravir/rilpivirine, nearly two-thirds reported willingness to try LAI antiretroviral therapy (ART). Most expressed preference for LAI over daily oral ART and had minimal concerns over potential LAI-ART use impacting reproductive health.
Medical subject headings
- HIV Infections
- Rilpivirine
- Pyridones
- Anti-HIV Agents
- Patient Preference